Online inquiry

IVTScrip™ mRNA-Human ACD, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK12420MR)

This product GTTS-WK12420MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ACD protein. This product can be used in Natural killer T (NKT) cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001082486.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 65057
UniProt ID Q96AP0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ACD, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK12420MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK13659MR IVTScrip™ mRNA-Human ACTG1, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACTG1
GTTS-WK8967MR IVTScrip™ mRNA-Human ADRA2A, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADRA2A
GTTS-WK16164MR IVTScrip™ mRNA-Human ANXA6, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANXA6
GTTS-WK23408MR IVTScrip™ mRNA-Human APH1B, (Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA APH1B
GTTS-WK5385MR IVTScrip™ mRNA-Human FSHR, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FSHR
GTTS-WK12379MR IVTScrip™ mRNA-Human ABLIM2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABLIM2
GTTS-WK13161MR IVTScrip™ mRNA-Human ADORA2B, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADORA2B
GTTS-WK22972MR IVTScrip™ mRNA-Human ARPC5L, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ARPC5L
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW